Mariastefania Antica

Mariastefania Antica graduated from the Faculty of Science, Zagreb University, Croatia in 1981. She obtained and her PhD in Immunology from Ludwig Maximilian’s University, Munich, Germany in 1987 prior to becoming a visiting scientist (WEHI, Melbourne, Australia, 1990-1994, Institute of Immunology, Munich, Germany, 1996, Mayo Clinic, Rochester, USA, 1998), and a principal investigator of national and international scientific projects. She is employed as Senior Scientist at the Rudjer Boskovic Institute, and a professor at the Faculty of Science in Zagreb, Croatia, teaching both undergraduate and graduate studies at the Faculty and Medical School, Zagreb University. In regard to her scientific achievements, she was awarded the National Science Award for young scientists (1984), the Award of the Academy of Sciences and Arts (1999), and the Award of Croatian Government (2000). She was the vice president of the Croatian Immunological Society from 1996 – 2001, editor of the Internet Journal of Hematology, and member of the Croatian Medical Journal Editorial Board. She is a life member of the UICC, and referee for international journals as well as European grant applications.

1books edited

1chapters authored

Latest work with IntechOpen by Mariastefania Antica

This book provides a comprehensive overview of he basic mechanisms underlying areas of acute leukemia, current advances, and future directions in management of this disease. The first section discusses the classification of acute leukemia, taking into account diagnoses dependent on techniques that are essential, and thankfully readily available, in the laboratory. The second section concerns recent advances in molecular biology, markers, receptors, and signaling molecules responsible for disease progression, diagnostics based on biochips and other molecular genetic analysis. These advances provide clinicians with important understanding and improved decision making towards the most suitable therapy for acute leukemia. Biochemical, structural, and genetic studies may bring a new era of epigenetic based drugs along with additional molecular targets that will form the basis for novel treatment strategies. Later in the book, pediatric acute leukemia is covered, emphasizing that children are not small adults when it comes to drug development. The last section is a collection of chapters about treatment, as chemotherapy-induced toxicity is still a significant clinical concern. The present challenge lies in reducing the frequency and seriousness of adverse effects while maintaining efficacy and avoiding over-treatment of patients.

Go to the book